Skip to main content
CV
NASDAQ Industrial Applications And Services

CapsoVision Launches $100M ATM Program Amid Widening Losses

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$6.6
Mkt Cap
$339.253M
52W Low
$3.434
52W High
$15.37
52W Position info
92% above low
Off High info
57% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CV sits 92% above its 52-week low of $3.434.

Summary

CapsoVision announced a $100M ATM offering with Cantor Fitzgerald and reported Q2 results with a $7.5M net loss and $9.1M cash balance.


Key Events · Financing and Capital Events · CV

  • $100M ATM Program Established

    CapsoVision entered a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell up to $100 million of common stock from time to time at market prices.

  • Q2 Loss Widens

    Net loss for Q2 2026 was $7.5 million, up from $4.6 million a year earlier, driven by higher R&D and G&A expenses.

  • Cash Position Tightens

    Cash and equivalents fell to $9.1 million as of June 30, 2026, from $10.1 million at year-end 2025, with operating cash burn of $14.5 million in the first half.

  • Regulatory Milestones Ahead

    Company expects FDA clearance of AI Highlights by end of Q3 2026 and plans a 510(k) submission for CapsoCam Colon in Q4 2026.


Analysis · CV · Industrial Applications And Services

CapsoVision entered a $100 million at-the-market equity offering agreement with Cantor Fitzgerald, giving the company a flexible financing tool but creating potential dilution for existing shareholders. The company also reported Q2 results showing a net loss of $7.5 million and cash of $9.1 million, underscoring the need for additional capital. The ATM program, combined with the company's going-concern warning from its last 10-Q, suggests management is proactively securing runway, though the overhang could pressure the stock.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.1% of the 1612 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CV was trading at $6.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $339.3M. The 52-week trading range was $3.43 to $15.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CV - Latest Insights

CV
Sep 28, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $6.78
Real-time Price: $6.31 info
Change: -$0.4727 (-7%) info
Market Cap: $335.491M info
CV
Sep 23, 2026, 9:01 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $6.10
Real-time Price: $6.31 info
Change: +$0.205 (+3%) info
Market Cap: $335.491M info
CV
Sep 18, 2026, 6:14 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $6.70
Real-time Price: $6.31 info
Change: -$0.395 (-6%) info
Market Cap: $335.491M info
CV
Sep 18, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.70
Real-time Price: $6.31 info
Change: -$0.395 (-6%) info
Market Cap: $335.491M info
CV
Sep 18, 2026, 2:33 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $6.67
Real-time Price: $6.31 info
Change: -$0.365 (-5%) info
Market Cap: $335.491M info